Every morning across Europe, the Middle East, and Africa, millions of people begin their day with a finger prick or an insulin injection. For many, it has become routine; checking glucose levels before breakfast, carrying insulin pens to work, or monitoring blood sugar before sleep. Behind these daily habits lies a fast-growing healthcare market centered around lancets and pen needles.
What looks like a small disposable medical product is now part of a billion-dollar diabetes care industry. The rise in diabetes cases across the EMEA region is quietly transforming demand for safer, thinner, and less painful injection devices.
According to the International Diabetes Federation (IDF), Europe had nearly 61 million adults living with diabetes in 2025. The Middle East and North Africa region recorded more than 73 million diabetic patients, one of the highest growth rates globally. In Africa, diabetes cases are expected to more than double by 2045 as urban lifestyles, obesity, and processed food consumption continue to rise.
This growing patient population is creating enormous recurring demand for lancets, safety lancets, insulin pen needles, and glucose monitoring accessories.
Europe’s Aging Population Is Changing Diabetes Care
In countries like Germany, France, Italy, and the United Kingdom, diabetes is increasingly linked with aging populations. Germany alone has more than 8 million diagnosed diabetic patients, while the UK reports over 5 million people living with diabetes or prediabetes.
Healthcare systems across Europe are gradually shifting diabetes care away from hospitals and toward home-based management. Patients are now expected to self-monitor blood glucose levels multiple times a day and administer insulin independently.
That shift has changed the way medical device companies design products.
Patients no longer want thick, painful needles. They prefer shorter 4mm pen needles, ultra-thin lancets, and devices that are easier to carry and safer to dispose of. European healthcare providers are also prioritizing products that reduce accidental needlestick injuries among nurses and caregivers.
The result is a steady rise in demand for safety-engineered lancets and premium pen needle technologies.
The Middle East Is Becoming One of the Fastest Growing Markets
The diabetes crisis is even more severe in parts of the Middle East.
Saudi Arabia, Kuwait, and the UAE consistently rank among countries with the highest diabetes prevalence globally. In some Gulf nations, nearly 1 in 5 adults is diabetic.
Rapid urbanization, high sugar consumption, obesity, and sedentary lifestyles are major contributors. Governments are now investing heavily in diabetes awareness programs, smart healthcare systems, and early screening initiatives.
Saudi Arabia’s healthcare spending crossed USD 50 billion in recent years, with a significant portion allocated to chronic disease management. As insulin usage rises, demand for pen needles and glucose testing products is increasing across retail pharmacies, hospitals, and online healthcare platforms.
Unlike Europe, where the market is mature, the Middle East still offers major expansion opportunities for device manufacturers.
The Companies Quietly Dominating the Market
| Company | Estimated Revenue (2025) | Key Focus Area |
|---|---|---|
| Becton Dickinson and Company | Over USD 20 Billion | Pen needles, syringes, diabetes injection systems, safety devices |
| Novo Nordisk | Over USD 42 Billion | Insulin products, insulin pens, diabetes care ecosystem |
| Ypsomed Holding AG | Over CHF 600 Million | Self-injection systems, insulin delivery devices, pen needles |
| Terumo Corporation | Over USD 6 Billion | Diabetes care devices, syringes, pen needle technologies |
| Roche | Over USD 72 Billion | Glucose monitoring systems, diabetes diagnostics |
| Sanofi | Over USD 48 Billion | Insulin therapies, diabetes treatment products |
| Medtronic | Over USD 32 Billion | Insulin pumps, diabetes management technologies |
Several global medical technology companies control a large share of the EMEA lancet and pen needles market, but competition has intensified as regional manufacturers expand aggressively.
Becton Dickinson and Company — The Largest Needle Player
Becton Dickinson, commonly known as BD, remains one of the strongest players in diabetes injection devices worldwide.
The company generated more than USD 20 billion in annual revenue in fiscal 2025, with its Medical Segment contributing heavily through injection systems, syringes, pen needles, and diabetes care products.
BD’s pen needles are widely used across European hospitals and pharmacies because of their compatibility with major insulin pen brands. The company has invested heavily in ultra-fine needle technologies designed to reduce pain perception during injections.
BD also benefits from strong distribution networks across Germany, France, Spain, and the UK.
Novo Nordisk — Building an Entire Diabetes Ecosystem
Novo Nordisk is not only one of the world’s largest insulin manufacturers but also a major force in insulin delivery systems.
The Danish company reported more than USD 42 billion in revenue in 2025, driven largely by diabetes and obesity care products. Europe and emerging Middle Eastern markets remain critical growth regions for the company.
Novo Nordisk’s insulin pens and compatible pen needles are used by millions of diabetic patients globally. The company has increasingly focused on connected diabetes care, combining smart insulin pens, digital monitoring tools, and patient tracking systems.
Its strong presence in Gulf countries is supported by partnerships with hospitals and government diabetes programs.
Ypsomed Holding AG — The Specialist in Injection Systems
Switzerland-based Ypsomed has become one of Europe’s most recognized diabetes device specialists.
Unlike diversified healthcare giants, Ypsomed focuses strongly on self-injection systems and insulin delivery technologies. The company reported annual revenues exceeding CHF 600 million in 2025, supported by strong sales of pen needles and autoinjector systems.
Ypsomed’s products are particularly popular among patients seeking comfortable self-administration devices with ergonomic designs.
The company has also expanded manufacturing capacity in Europe to meet growing demand for high-precision injection systems.
Owen Mumford — A Mid-Sized Company Competing Through Innovation
UK-based Owen Mumford may not match the scale of BD or Novo Nordisk, but it has carved out a strong position in safety lancets and injection devices.
The company is known for developing single-use safety lancets designed to minimize contamination risks and accidental injuries. Its products are widely supplied to clinics, diagnostic laboratories, and hospitals across Europe and the Middle East.
Mid-sized companies like Owen Mumford are gaining traction because many healthcare providers are seeking affordable alternatives without compromising safety standards.
A Market Built on Repetition
Unlike many medical products purchased once, lancets and pen needles are used daily and repeatedly.
A patient managing diabetes may use hundreds of lancets and pen needles every year. This creates a recurring revenue model for manufacturers and distributors.
Pharmacies, online healthcare stores, hospitals, and diabetes clinics have become key sales channels throughout the EMEA region. E-commerce has also started reshaping the market as patients increasingly order diabetes care supplies online for convenience and lower costs.
Market Snapshot
| Segment | Key Insight |
|---|---|
| Largest Region | Europe |
| Fastest Growing Region | Middle East |
| Most Used Product | Disposable Pen Needles |
| Key Driver | Rising Diabetes Cases |
| Popular Needle Size | 4mm Ultra-Fine Pen Needles |
| Major End Users | Homecare Patients |
| Leading Companies | BD, Novo Nordisk, Ypsomed |
| Emerging Trend | Smart Diabetes Management |
The Future of the Market Lies in Comfort and Convenience
The future of the EMEA lancet and pen needles market will not be shaped only by rising diabetes numbers. It will depend on how comfortable, painless, and convenient companies can make diabetes management.
Patients increasingly expect devices that are smaller, safer, and easier to use. Healthcare systems want products that reduce hospital visits and support home treatment. Governments want better chronic disease management without overwhelming healthcare budgets.
For manufacturers, even the smallest innovation in needle design can make a major commercial difference when millions of patients rely on these products every single day.
Get Access to the Dashboard
Everything you need to understand the Pen Needles Market is now in one place. From stats and country insights to competitor strategies, our expert-built dashboard makes it easy to analyze and act. Visit now and access the customized dashboard to stay on top of the market.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting delivers strategic insights across the medical devices market, including diagnostic devices, surgical equipment, imaging systems, wearable technologies, cardiovascular devices, and orthopedic implants. We help healthcare innovators track market trends, optimize product strategies, and drive growth through data-driven intelligence and industry expertise.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
Read More: